1. Home
  2. NVCT

as 07-17-2024 12:36pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Founded: 2020 Country:
United States
United States
Employees: N/A City: FORT LEE
Market Cap: 124.3M IPO Year: 2022
Target Price: $21.00 AVG Volume (30 days): 125.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.41 EPS Growth: N/A
52 Week Low/High: $5.85 - $15.50 Next Earning Date: 08-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

NVCT Daily Stock ML Predictions

Stock Insider Trading Activity of Nuvectis Pharma Inc. (NVCT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
BENTSUR RON NVCT Chairman & CEO May 14 '24 Buy $6.74 1,940 $13,075.60 3,246,424 SEC Form 4
BENTSUR RON NVCT Chairman & CEO May 10 '24 Buy $6.40 2,000 $12,800.00 3,244,484 SEC Form 4
Poradosu Enrique NVCT Chief Science & Business Off May 10 '24 Buy $6.29 500 $3,145.00 1,504,319 SEC Form 4
Shemesh Shay NVCT Chief Dev. & Ops. Officer May 10 '24 Buy $6.32 1,113 $7,034.16 1,493,068 SEC Form 4
BENTSUR RON NVCT Chairman & CEO Mar 18 '24 Buy $10.29 5,000 $51,450.00 3,242,484 SEC Form 4

Share on Social Networks: